Barclays analyst Gena Wang maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $418.00. The company’s shares opened today at $395.72.

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the other stocks Jim Cramer talked about this week. Jim Cramer, host of Mad ...

BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) for potential securities law violations. Investors who have lost money in ...

Hardman Johnston Global Equity highlighted stocks like Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), in the third quarter 2024 investor letter. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ...

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals VRTX. And retail traders should know. We noticed this today when the trades showed up on publicly ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Low PE Investor model based on the published ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our Low PE Investor model based on the published ...

Vertex Pharmaceuticals (VRTX) closed at $469.29 in the latest trading session, marking a -0.99% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.3%.